Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other financing activities: 2014-2023

Historic Other financing activities for Viking Therapeutics (VKTX) over the last 4 years, with Mar 2023 value amounting to $37,000.

  • Viking Therapeutics' Other financing activities was N/A to $37,000 in Q1 2023 from the same period last year, while for Mar 2023 it was $346,000, marking a year-over-year change of. This contributed to the annual value of $22,000 for FY2022, which is 52.17% down from last year.
  • Viking Therapeutics' Other financing activities amounted to $37,000 in Q1 2023, which was up 94.74% from $19,000 recorded in Q4 2021.
  • Over the past 5 years, Viking Therapeutics' Other financing activities peaked at $37,000 during Q1 2023, and registered a low of $7,000 during Q4 2019.
  • In the last 2 years, Viking Therapeutics' Other financing activities had a median value of $28,000 in 2021 and averaged $28,000.
  • Data for Viking Therapeutics' Other financing activities shows a maximum YoY tumbled of 97.53% (in 2019) over the last 5 years.
  • Over the past 3 years, Viking Therapeutics' Other financing activities (Quarterly) stood at $7,000 in 2019, then followed by $19,000 in 2021, then followed by $37,000 in 2023.
  • Its Other financing activities was $37,000 in Q1 2023, compared to $19,000 in Q4 2021 and $7,000 in Q4 2019.